ArticleMedical oncology (Northwood, London, England)2025
EGF induces SOD activity, TNF-α/IL-6 expression and complement regulatory proteins in cervical cancer cells: suppression by EGCG.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papilloma virus (HPV) infection is known to induce chronic inflammation and trigger oncogenesis. The present study is intended to understand the role of EGF on the secretion of inflammatory cytokines by CC and to assess the anti-inflammatory efficacy of EGCG under basal and EGF-stimulated conditions. EGCG inhibited the EGF-induced phosphorylation of EGFR at Y992 and AKT at S473 in CC cells. Further, we showed that EGCG is capable of inhibiting the proliferation in 2D and elevating apoptosis in 2D and 3D spheroid culture via increased ROS generation and decreasing SOD enzymatic activity in both HPV positive ME180 and HPV negative C33A cells under basal and EGF-stimulated conditions. The mRNA expression of SOD1/2 along with their enzymatic activity, tumor necrosis factor-α (TNF-α) and programmed death-ligand 1 (PD-L1) transcripts was found to be downregulated by EGCG. The increase in inflammatory markers such as interleukin 6 (IL-6), C reactive protein (CRP) and TNF-α were elevated upon EGF treatment. The critical contributing molecules produced by CC cells that are reported to engage immune cells such as CD46, CD55 and CD59 levels are downregulated by EGCG. Pre-treatment with EGCG blocked EGF-induced changes in CC cells. Collectively, these findings indicate the inflammatory role for EGF and attest the anti-inflammatory potential of EGCG in CC cells.
Indexed as
Identifiers
41284161What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.